Lexaria's DehidaTECH-seglutide在第一阶段b试验中显示,安全性有所改善,与Rybelsus类似。 Lexaria's DehydraTECH-semaglutide showed improved safety and similar efficacy to Rybelsus® in a Phase 1b trial.

Lexaria生物科学公司宣布其第1b阶段研究GLP-1-H24-4达到其主要终点,表明其脱水TECH-硫化物配方在16周内是安全的和良好的,其总体不良事件减少47.9%,肠胃副作用比Rybelsus少54.9%。 Lexaria Bioscience Corp. announced its Phase 1b study GLP-1-H24-4 met its primary endpoint, showing its DehydraTECH-semaglutide formulation was safe and well-tolerated over 16 weeks, with 47.9% fewer overall adverse events and 54.9% fewer gastrointestinal side effects than Rybelsus®. 所有脱水TECH配方都减少恶心、呕吐和腹泻。 All DehydraTECH formulations reduced nausea, vomiting, and diarrhea. HBA1c的减少量与Rybelsus相似,尽管经批准的药物的重量减幅更大。 HbA1c reductions were comparable to Rybelsus®, though weight loss was greater with the approved drug. 该公司在两项融资中筹集750万美元,将其发展跑道延长到2026年,并在今后的研究披露之前与合作伙伴分享成果。 The company raised $7.5 million in two financings, extending its development runway into 2026, and shared results with a partner ahead of future research disclosures.